About CKLF-like MARVEL transmembrane domain-containing protein 2
CKLF-like MARVEL transmembrane domain-containing protein 2 (CMTM2) is a protein
from Homo sapiens identified by UniProt accession
Q8TAZ6, 248 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | CKLF-like MARVEL transmembrane domain-containing protein 2 |
|---|
| UniProt accession | Q8TAZ6 |
|---|
| Gene | CMTM2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 248 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (43)
Diseases linked to this target (Open Targets).
- Agouti-related protein measurement · score 0.10
- hepatocellular carcinoma · score 0.09
- gonorrhea · score 0.05
- Crohn's disease · score 0.04
- lung adenocarcinoma · score 0.04
- neoplasm · score 0.03
- chronic hepatitis B virus infection · score 0.03
- varicocele · score 0.02
- blood protein measurement · score 0.02
- response to risperidone · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TAZ6-F1 | alphafold | PREDICTED | 66.31 | — |
Amino-acid sequence (248 residues)
MAPKAAKGAK PEPAPAPPPP GAKPEEDKKD GKEPSDKPQK AVQDHKEPSD KPQKAVQPKH EVGTRRGCRR YRWELKDSNK EFWLLGHAEI KIRSLGCLIA AMILLSSLTV HPILRLIITM EISFFSFFIL LYSFAIHRYI PFILWPISDL FNDLIACAFL VGAVVFAVRS RRSMNLHYLL AVILIGAAGV FAFIDVCLQR NHFRGKKAKK HMLVPPPGKE KGPQQGKGPE PAKPPEPGKP PGPAKGKK
Explore CKLF-like MARVEL transmembrane domain-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets